-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Reiterates Buy on Krystal Biotech, Maintains $361 Price Target

Benzinga·10/15/2026 17:20:05
Listen to the news
HC Wainwright & Co. analyst Joseph Pantginis reiterates Krystal Biotech (NASDAQ:KRYS) with a Buy and maintains $361 price target.